Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasms 2Tobacco Use Disorder 1Smoking Cessation 1Skin Neoplasms 1Noncommunicable Diseases 1Neoplasms, Squamous Cell 1Neoplasms, Basal Cell 1Melanoma 1Lymphatic Abnormalities 1Lymphangioma 1Lung Neoplasms 1Ischemic Stroke 1Chronic Disease 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Behavior 1Abdomen, Acute 1

Interventions

aldesleukin 9Interleukin-2 9Nivolumab 7fludarabine phosphate 6Dacarbazine 6Cyclophosphamide 6fludarabine 5Temozolomide 4Ipilimumab 4Fluorouracil 4montanide ISA 51 3Surveys and Questionnaires 3Semaxinib 3Radiotherapy 3Radiation 3Mohs Surgery 3Educational Status 3Cisplatin 3Allovectin-7 3zanolimumab 2talabostat 2sonidegib 2poly ICLC 2binimetinib 2Whole-Body Irradiation 2Vinblastine 2Vemurafenib 2Tacrolimus 2Tablets 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Skin Neoplasms × Risk Factors × Clear all
NCT03509467 2025-12-19

Using MC1R Genotype to Impact Melanoma Risk Behavior

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
2,054 enrolled 92 charts
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms, Neoplasms, Basal Cell, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡